Kite Pharma (KITE) Q2 Loss Wider But Focus Is On KTE-C19
Tuesday, August 9, 2016 10:35 AM EDT
Kite’s research and development expenses shot up 185.5% from the year-ago period to $47.4 million in the reported quarter, general and administrative expenses were $23.5 million, up 140.6% from the year-ago period.